# Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis

> **NCT01955980** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pari Pharma GmbH** · enrollment: 19 (actual)

## Conditions studied

- Rhinosinusitis

## Interventions

- **DRUG:** Budesonide
- **DRUG:** Budesonide

## Key facts

- **NCT ID:** NCT01955980
- **Lead sponsor:** Pari Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-27
- **Primary completion:** 2018-09-27
- **Final completion:** 2021-07-29
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2022-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01955980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01955980, "Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01955980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*